| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 114.51% | HC Wainwright & Co. | → $144 | Reiterates | Buy → Buy |
| 07/25/2023 | 63.86% | Barclays | $120 → $110 | Maintains | Overweight |
| 06/02/2023 | 114.51% | HC Wainwright & Co. | $135 → $144 | Reiterates | Buy → Buy |
| 02/21/2023 | 41.52% | Benchmark | → $95 | Reiterates | → Buy |
| 12/23/2022 | 34.07% | Roth Capital | $85 → $90 | Maintains | Buy |
| 11/21/2022 | 78.76% | Barclays | $150 → $120 | Maintains | Overweight |
| 10/25/2022 | 123.45% | Barclays | $157 → $150 | Maintains | Overweight |
| 09/02/2022 | 160.69% | Roth Capital | $185 → $175 | Maintains | Buy |
| 07/05/2022 | 133.87% | Barclays | $165 → $157 | Maintains | Overweight |
| 05/16/2022 | 93.65% | Stephens & Co. | $153 → $130 | Maintains | Overweight |
| 02/22/2022 | 93.65% | Benchmark | $180 → $130 | Maintains | Buy |
| 02/18/2022 | 145.79% | Barclays | $185 → $165 | Maintains | Overweight |
| 09/22/2021 | 168.14% | Barclays | $174 → $180 | Maintains | Overweight |
| 07/30/2021 | 183.03% | Roth Capital | $200 → $190 | Maintains | Buy |
| 05/04/2021 | 183.03% | Barclays | $198 → $190 | Maintains | Overweight |
| 02/04/2021 | 194.95% | Barclays | $145 → $198 | Maintains | Overweight |
| 02/04/2021 | 197.93% | Roth Capital | $195 → $200 | Maintains | Buy |
| 02/04/2021 | 361.79% | HC Wainwright & Co. | $229 → $310 | Maintains | Buy |
| 10/21/2020 | 190.48% | Craig-Hallum | $215 → $195 | Maintains | Buy |
| 09/29/2020 | 190.48% | Roth Capital | $190 → $195 | Reiterates | → Buy |
| 08/04/2020 | 116% | Barclays | $134 → $145 | Maintains | Overweight |
| 04/08/2020 | 241.13% | HC Wainwright & Co. | $237 → $229 | Maintains | Buy |
| 03/24/2020 | — | Argus Research | Downgrades | Buy → Hold | |
| 03/10/2020 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 02/06/2020 | — | Benchmark | Initiates Coverage On | → Buy | |
| 09/19/2019 | 96.63% | Barclays | $110 → $132 | Upgrades | Equal-Weight → Overweight |
| 08/05/2019 | 63.86% | Barclays | $131 → $110 | Maintains | Equal-Weight |
| 06/11/2019 | 95.14% | Barclays | → $131 | Initiates Coverage On | → Equal-Weight |
| 09/19/2018 | 302.2% | HC Wainwright & Co. | $257 → $270 | Maintains | Buy |
| 08/17/2018 | 281.35% | Goldman Sachs | → $256 | Initiates Coverage On | → Neutral |
What is the target price for Ligand Pharmaceuticals (LGND)?
The latest price target for Ligand Pharmaceuticals (NASDAQ: LGND) was reported by HC Wainwright & Co. on August 9, 2023. The analyst firm set a price target for $144.00 expecting LGND to rise to within 12 months (a possible 114.51% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ligand Pharmaceuticals (LGND)?
The latest analyst rating for Ligand Pharmaceuticals (NASDAQ: LGND) was provided by HC Wainwright & Co., and Ligand Pharmaceuticals reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Ligand Pharmaceuticals (LGND)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ligand Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ligand Pharmaceuticals was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
Is the Analyst Rating Ligand Pharmaceuticals (LGND) correct?
While ratings are subjective and will change, the latest Ligand Pharmaceuticals (LGND) rating was a reiterated with a price target of $0.00 to $144.00. The current price Ligand Pharmaceuticals (LGND) is trading at is $67.13, which is within the analyst's predicted range.